AstraZeneca Aktie

146,10EUR 2,20EUR 1,53%
AstraZeneca für 0 Euro bei ZERO ordern (zzgl. Spreads)
WKN: 886455 / ISIN: GB0009895292
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Aktionärsstruktur

Inhaber in %
Freefloat 94,45
Government Pension Fund - Global (The) 2,28
Vanguard Total International Stock Index Fund 1,34
Vanguard Health Care Fund 1,18
American Funds New Perspective Fund 0,99
Goldman Sachs GQG Partners International Opportunities Fund 0,89

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2019 2020 2021 2022 2023
Personal am Ende des Jahres 70 600 76 100 83 100 83 500 89 900
Umsatz pro Mitarbeiter in Mio. EUR 0,27 0,28 0,33 0,43 0,41

Bilanz (in Mio. EUR) - Aktiva

2019 2020 2021 2022 2023
Summe Umlaufvermögen 11 748 14 298 19 376 18 782 19 653
Summe Anlagevermögen 23 668 26 337 51 718 55 091 53 157
Summe Aktiva 46 331 48 816 77 790 80 209 79 321

Bilanz (in Mio. EUR) - Passiva

2019 2020 2021 2022 2023
Gesamtverschuldung/ -verbindlichkeiten 13 759 14 909 22 726 24 301 22 452
Summe Fremdkapital 35 313 37 376 48 784 49 401 48 598
Summe Eigenkapital 11 018 11 440 29 006 30 807 30 723
Summe Passiva 46 331 48 816 77 790 80 209 79 321

Adresse

Cambridge Biomedical Campus, CB2 0AA Cambridge
Telefon +44 (20) 3749-5000
Internet http://www.astrazeneca.co.uk

Management

Adrian Charles Noel Kemp
Secretary
Alberto Hegewisch
Chief Medical Officer
Andreas Rummelt
Non-Executive Director
Anna Olive Magdelene Manz
Non-Executive Director
Aradhana Sarin
Chief Financial Officer & Executive Director
Cindy L. Hoots
Chief Digital & Information Officer
David Fredrickson
Executive Vice President-Oncology Business Unit
Deborah DiSanzo
Independent Non-Executive Director
Diana Layfield
Non-Executive Director
Euan A. Ashley
Non-Executive Director
Helen MacPhee
Vice President
Iskra Reic
EVP-Vaccines & Immune Therapies
Jeffrey Pott
CHRO, Chief Compliance Officer & General Counsel
Jonathan Thomas Charles Slade
Group Treasurer
Kevin G. Lokay
Head-Change Implementation
Marc Pierre Jean Dunoyer
Chief Strategy Officer
Marcus Wallenberg
Independent Non-Executive Director
Margareta Elisabeth Björk
Senior VP & Head-Late-stage Development
Michel Demaré
Chairman
Nazneen Rahman
Independent Non-Executive Director
Pam P. Cheng
Executive VP-Operations & Information Technology
Pascal Soriot
Chief Executive Officer & Executive Director
Philip Arthur John Broadley
Senior Independent Non-Executive Director
Regina Fritsche Danielson
SVP, Head-Research & Early Development
Ruud Dobber
Executive VP-Biopharmaceuticals Business
Sharon Barr
EVP-BioPharmaceuticals Research & Development
Sherilyn D. McCoy
Independent Non-Executive Director
Shu Kam Mok
Independent Non-Executive Director
Sjoerd Hubben
Vice President-Global Government Affairs & Policy
Susan Mary Galbraith
Executive VP-Oncology Research & Development
Tyrell J. Rivers
Executive Director-Corporate Development